All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
Dual Pricing Strategy Addresses Unique US Payer Priorities
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
You may also be interested in...
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
AbbVie’s $2.1bn write down of Imbruvica’s value is tied directly to Medicare drug price negotiations. Humira’s US biosimilar erosion continued as projected, while the Skyrizi/Rinvoq duo are set to top Humira peak sales by 2027.